NASDAQ
06.06.25 | 21:59
13,120 US-Dollar
+0,46 % +0,060
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | LENSAR, Inc.: LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 32 | GlobeNewswire (Europe) | ORLANDO, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR's board of directors granted... ► Artikel lesen | |
| 27.05. | FTC Requests More Information on Alcon's $430 Million Acquisition of Lensar | 13 | CPI | ||
| 22.05. | LENSAR, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.05. | LENSAR, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 08.05. | LENSAR, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.05. | LENSAR, Inc.: LENSAR Reports First Quarter 2025 Results and Provides Business Update | 61 | GlobeNewswire (Europe) | 14 ALLY Robotic Laser Cataract Systems ("ALLY Systems") placed in 1Q 2025 with an additional backlog of 24 systems pending installation as of March 31, 2025 34% Revenue growth over the first... ► Artikel lesen | |
| 25.03. | ALC Stock Rises Following the Merger Agreement With LENSAR | 1 | Zacks | ||
| LENSAR Aktie jetzt für 0€ handeln | |||||
| 24.03. | BTIG cuts LENSAR stock rating post Alcon acquisition deal | 5 | Investing.com | ||
| 24.03. | M&A Snapshot: Alcon to acquire LENSAR to boost its cataract equipment portfolio | 6 | Seeking Alpha | ||
| 24.03. | Alcon agrees to acquire Lensar and its robotic cataract laser system | 3 | MassDevice | ||
| 24.03. | Alcon Agrees To Acquire LENSAR For Up To Approximately $430 Mln | 447 | AFX News | WASHINGTON (dpa-AFX) - Eye care company Alcon, Inc. (ALC) and medical technology company LENSAR, Inc. (LNSR) announced Monday the companies have entered into a definitive merger agreement through... ► Artikel lesen | |
| 24.03. | Alcon übernimmt Medtech-Unternehmen Lensar für bis zu 430 Millionen Dollar | 569 | Moneycab | Genf - Der Augenheilkundespezialist Alcon kauft in den USA zu. Für bis zu 430 Millionen Dollar übernimmt das Genfer Unternehmen das Medizintechnikunternehmen Lensar aus den USA. Lensar ist laut einer... ► Artikel lesen | |
| 24.03. | Alcon agrees to acquire LENSAR for $14.00 per share | 6 | Seeking Alpha | ||
| 24.03. | Alcon übernimmt LENSAR für bis zu 430 Millionen US-Dollar | 5 | Investing.com Deutsch | ||
| 24.03. | LENSAR, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 24.03. | Alcon Agrees to Acquire LENSAR, Inc. | 353 | Business Wire | Acquisition of ALLY Robotic Cataract Laser Systems strengthens Alcon's cataract equipment and technology portfolio Next generation technology will be expanded globally, improving the efficiency... ► Artikel lesen | |
| 06.03. | LENSAR - Top Healthcare Equipment Stock | 4 | Barchart.com | ||
| 04.03. | LENSAR, Inc.: LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 112 | GlobeNewswire (Europe) | ORLANDO, Fla., March 03, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR's board of directors... ► Artikel lesen | |
| 28.02. | LENSAR, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 10 | SEC Filings | ||
| 27.02. | LENSAR, Inc. - 10-K, Annual Report | 1 | SEC Filings |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CARL ZEISS MEDITEC | 60,10 | +1,43 % | Carl Zeiss Meditec - Günstig bewertet; Foerst muss es jetzt richten | In den beiden ersten Teilen unserer Serie zu Carl Zeiss Meditec haben wir die jüngsten Führungswechsel und die kurzzeitigen Hemmnisse im Geschäftsmodell beleuchtet. Im dritten Teil prüfen wir, ob die... ► Artikel lesen | |
| ROKU | 68,76 | -0,16 % | Roku TV sluggish? My go-to fix can revitalize its performance in just seconds | ||
| HIMS & HERS HEALTH | 48,990 | -0,97 % | SCHOCK bei Renk, Novo Nordisk Aktie "KAUFEN", PanGenomic Health auf den Spuren von Hims & Hers | Schock bei Renk & Co.! Gestern Nachmittag machte die Nachricht die Runde, dass die EU den Rüstungskonzernen an die Milliardengewinne gehen will. Schließlich stehen die Unternehmen vor goldenen Zeiten.... ► Artikel lesen | |
| MEDICLIN | 2,960 | 0,00 % | Ihre wichtigsten Termine: Heute im Fokus: Airbnb, Auto1, Ströer, Renk, Cewe Stiftung, Mediclin und VDMA | © Foto: NurPhoto | Lorenzo Di Cola - picture allianceGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports First Quarter 2025 Financial Results and Provides Business Update | SAN DIEGO, May 15, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCPK: EVFM), today announced financial results for the first quarter... ► Artikel lesen | |
| EMEIS | 10,210 | +0,39 % | emeis S.A.: emeis: Documents and Information Related to the Combined General Meeting of 26 June 2025 | Regulatory News:
The Combined General Meeting (Ordinary and Extraordinary) of Shareholders of emeis S.A. (Paris:EMEIS) (the Company ») will be held on Thursday 26 June 2025 at 9:30 a.m. (Paris... ► Artikel lesen | |
| VERU | 0,525 | -3,40 % | Veru Inc.: Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide ... | --Phase 2b QUALITY clinical study topline safety data shows that the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone-- --Based on Phase 2b QUALITY trial... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 5,240 | -100,00 % | Tempest Therapeutics, Inc. - 8-K, Current Report | ||
| LIFEWARD | 1,200 | +0,84 % | Lifeward Ltd.: Finanzvorstand Michael Lawless kündigt Rücktritt an | ||
| SENSEONICS | 0,460 | -0,69 % | Senseonics Holdings, Inc. to Host In-Person and Virtual Analyst Event at ADA 2025: Eversense 365 Continuous Glucose Monitoring System for People with Diabetes | ||
| CLOVER HEALTH INVESTMENTS | 2,645 | -1,34 % | Clover Health Investments, Corp.: Clover Health Appoints Industry Veteran as Chief Medical Officer of Medicare Advantage | WILMINGTON, Del., April 07, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) ("Clover," "Clover Health" or the "Company"), today announced the appointment of Dr. Shelly Gupta... ► Artikel lesen | |
| BONESUPPORT | 24,980 | +0,08 % | Bonesupport Holding AB: Upcoming CEO change. Emil Billbäck will transfer to a role as Senior Advisor. Torbjörn Sköld will start as CEO effective September 1st, 2025 | BONESUPPORT, a leading company in orthobiologics for the management of bone injuries, today announces the coming transition of leadership at Bonesupport.
Lennart Johansson states: Emil Billbäck will... ► Artikel lesen | |
| EKSO BIONICS | 0,257 | 0,00 % | XFRA NEW INSTRUMENTS AVAILABLE ON 02.06.2025 | The following instruments on XETRA do have their first trading 02.06.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 02.06.2025
Aktien
1 LU0445408270 Altisource Portfolio... ► Artikel lesen | |
| SURGICAL SCIENCE SWEDEN | 13,640 | -0,29 % | Surgical Science Sweden AB: Interim report January - March 2025: Strong growth despite macroeconomic uncertainties | First quarter 2025 (Jan-Mar)
Net sales amounted to SEK 250.7 (188.2) million, an increase of 33 percent compared with the corresponding period in the preceding year. SEK 18.3 million was acquired revenue.License... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 46,650 | +0,26 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen |
LENSAR INC gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 13,120 Euro und damit +0,46 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LENSAR INC finden Sie auf Wallstreet Online.